<DOC>
	<DOCNO>NCT00005048</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine estramustine paclitaxel treat patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Estramustine Paclitaxel Treating Patients With Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) paclitaxel estramustine patient hormone refractory prostate cancer . II . Evaluate toxicity combination MTD paclitaxel patient population . III . Determine objective tumor response arise treatment patient . OUTLINE : This dose escalation study paclitaxel . Patients receive oral estramustine daily day 1-3 paclitaxel IV 1 hour day 3 weekly 6 week follow 1 week rest . Treatment continue least 2 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A minimum 18 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate progressive systemic disease despite least 1 endocrine manipulation include 1 following : Orchiectomy LHRH analogue without flutamide , megestrol , diethylstilbestrol Flutamide must discontinue least 2 week PSA stabilize normal rise Measurable evaluable disease No brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Greater 2 month Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1 mg/dL SGOT great 2 time upper limit normal Renal : Creatinine le 2 mg/dL Hydronephrosis impair renal function must decompress adequately Cardiovascular : No severe cardiac ( i.e. , symptomatic arrhythmia require medication active congestive heart failure ) coronary disease unstable despite medication Other : Adequate nutritional status ( least 1,500 Kcal/day ) No significant active medical illness would preclude study therapy survival No malignancy within past 5 year except adequately treat basal squamous cell carcinoma skin No acute spinal cord compression PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic response modifier Chemotherapy : No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 2 week since prior corticosteroid No concurrent exogenous corticosteroid except document CNS metastases adrenal insufficiency Concurrent hormones nondisease condition allow ( e.g. , insulin diabetes mellitus ) Concurrent continuation monthly hormonal therapy LHRH agonist DES require Radiotherapy : Prior radiation symptomatic metastatic site allow provide measurable evaluable lesion At least 2 week since prior radiotherapy recover No concurrent radiotherapy No concurrent palliative radiotherapy except whole brain irradiation document CNS disease impend spinal cord compression Surgery : See Disease Characteristics At least 3 week since prior surgery recover Other : No concurrent treatment prostate cancer except pain palliation</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2000</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>